Óscar Barbero-Úriz

Mr. Óscar Barbero-Úriz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ÓBÓscar Barbero-Úriz
Óscar Barbero-Úriz
MVMarta Valenti Valenti
Marta Valenti Valenti
MMMaría Molina Martín
María Molina Martín
TBTERESA FERNÁNDEZ-ACERO BASCONES
TERESA FERNÁNDEZ-ACERO BASCONES
VCVictor Cid
Victor Cid
The yeast Saccharomyces cerevisiae is the paradigm of a eukaryotic model organism. In virtue of a substantial degree of functional conservation, it has been extensively exploited to understand multiple aspects of the genetic, molecular, and cellular biology of human disease. Many aspects of cell signaling in cancer, aging, or metabolic diseases have been tackled in yeast. Here, we review the strategies undertaken throughout the years for the development of humanized yeast models to study regulated cell death (RCD) pathways in general, and specifically, those related to innate immunity and inflammation, with an emphasis on pyroptosis and necroptosis. Such pathways involve the assembly of distinct modular signaling complexes such as the inflammasome and the necrosome. Like other supramolecular organizing centers (SMOCs), such intricate molecular arrangements trigger the activity of enzymes, like caspases or protein kinases, culminating in the activation of lytic pore-forming final effectors, respectively, Gasdermin D (GSDMD) in pyroptosis and MLKL in necroptosis. Even though pathways related to those governing innate immunity and inflammation in mammals are missing in fungi, the heterologous expression of their components in the S. cerevisiae model provides a “cellular test tube” to readily study their properties and interactions, thus constituting a valuable tool for finding novel therapies.

3 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TFTeresa Fernandez-Acero
Teresa Fernandez-Acero
ÓBÓscar Barbero-Úriz
Óscar Barbero-Úriz
GGGema Gonzalez-Rubio
Gema Gonzalez-Rubio
MVMarta Valenti
Marta Valenti
MMMaría Molina Martín
María Molina Martín
VCVictor Cid
Victor Cid
SARS-CoV-2 is a positive-sense single-stranded RNA virus of the Coronaviridae family. Emerging coronaviruses posing pandemic risk and the swift appearance of new antigenic variants of circulating SARS-CoV-2 urge the need for new and diverse effective treatments. The most outstanding targets to inhibit viral replication are its cysteine-proteases, 3CLpro and PLpro, which are essential for virus life cycle. Here, we investigated the functional consequences of heterologously expressed SARS-CoV-2 proteases in the eukaryotic model Saccharomyces cerevisiae. Both overproduced 3CLpro and PLpro caused yeast growth inhibition. This phenotype was dependent on their protease activities, since it was abrogated by the expression of catalytically inactive mutants or counteracted by the treatment with known protease inhibitors. 3CLpro reproduced in yeast the proteolytic cleavage of the pore-forming protein Gasdermin D, previously described in human cell lines. We generated a yeast-based screening platform to detect mutations in 3CLpro conferring resistance to inhibitors. To this end, we evaluated the behaviour of the purported resistant mutant, 3CLproE166V, and found a resistant pattern to nirmatrelvir. Taking advantage of this model, we performed a random mutagenesis screen to isolate nirmatrelvir-resistant mutations in 3CLpro. Our screening identified nine clones. Five harbored previously described mutations, either identical (A260V) or involving alternative substitutions (G15N/F159I, G23E/D33N/R60K, C128R/R188K, S139I). Importantly, our study also revealed four novel residues that have not yet been associated with nirmatrelvir resistance (K88R, L220M, Y209F, L262M). In sum, we report a suitable model to screen compounds in search of new 3CLpro and PLpro inhibitors and to predict mutations associated to drug resistance.

12 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ÓBÓscar Barbero-Úriz
Óscar Barbero-Úriz
MVMarta Valenti Valenti
Marta Valenti Valenti
MMMaría Molina Martín
María Molina Martín
TBTERESA FERNÁNDEZ-ACERO BASCONES
TERESA FERNÁNDEZ-ACERO BASCONES
VCVíctor J. Cid
Víctor J. Cid
The yeast Saccharomyces cerevisiae is the paradigm of a eukaryotic model organism. In virtue of a substantial degree of functional conservation, it has been extensively exploited to understand multiple aspects of the genetics, molecular and cellular biology of human disease. Many aspects of cell signaling in cancer, aging or metabolic diseases, have been tackled in yeast. Here, we review the strategies undertaken through the years for the development of humanized yeast models to study regulated cell death (RCD) pathways in general, and specifically those related to innate immunity and inflammation, with emphasis in pyroptosis and necroptosis. Such pathways involve the assembly of distinct modular signaling complexes such as the inflammasome and the necrosome. Like other supramolecular organizing centers (SMOCs), such intricate molecular arrangements trigger the activity of enzymes, like caspases or protein kinases, culminating in the activation of lytic pore-forming final effectors, respectively gasdermin D (GSDMD) in pyroptosis and MLKL in necroptosis. Even though pathways related to those governing innate immunity and inflammation in mammals are missing in fungi, heterologous expression of their components in the S. cerevisiae model provides a “cellular test tube” to readily study their properties and interactions, thus constituting a valuable tool for finding novel therapies.

27 October 2026 in Antiviral Research
Verified
Journal Article
Open access
ÓBÓscar Barbero-Úriz
Óscar Barbero-Úriz
GGGema González-Rubio
Gema González-Rubio
MVMarta Valenti
Marta Valenti
MMMaría Molina Martín
María Molina Martín
VCVictor Cid
Victor Cid
TFTeresa Fernández-Acero
Teresa Fernández-Acero